5 analysts have expressed a variety of opinions on Elanco Animal Health ELAN over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 3 | 1 | 0 | 1 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 1 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $18.2, a high estimate of $23.00, and a low estimate of $14.00. This upward trend is evident, with the current average reflecting a 17.42% increase from the previous average price target of $15.50.
Understanding Analyst Ratings: A Comprehensive Breakdown
In examining recent analyst actions, we gain insights into how financial experts perceive Elanco Animal Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Balaji Prasad | Barclays | Raises | Overweight | $23.00 | $19.00 |
| David Westenberg | Piper Sandler | Raises | Neutral | $18.00 | $12.00 |
| Nathan Rich | Goldman Sachs | Raises | Sell | $14.00 | $12.50 |
| Erin Wright | Morgan Stanley | Raises | Overweight | $17.00 | $16.00 |
| Balaji Prasad | Barclays | Raises | Overweight | $19.00 | $18.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Elanco Animal Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Elanco Animal Health compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Elanco Animal Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Elanco Animal Health's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Elanco Animal Health analyst ratings.
Discovering Elanco Animal Health: A Closer Look
Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production. The company's product portfolio of approximately 200 brands.
Financial Milestones: Elanco Animal Health's Journey
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Elanco Animal Health displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 5.08%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Elanco Animal Health's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -13.62%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Elanco Animal Health's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -2.28%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Elanco Animal Health's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.98%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Elanco Animal Health's debt-to-equity ratio is below the industry average. With a ratio of 0.93, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
What Are Analyst Ratings?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
